MedTrace Logo

Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants

NCT04323124 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of single and multiple ascending oral doses of PF-07059013 in healthy adult participants. Additionally, effects of different formulations and food on parameters, including PK may be explored.

Conditions

  • Healthy

Interventions

DRUG

PF-07059013

Participants will recieve PF-07059013

DRUG

Placebo

Participants will recieve placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-17
Primary Completion
2021-10-21
Completion
2021-10-21

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04323124 on ClinicalTrials.gov